Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Volvo has slightly scaled back its once ambitious electric plans, but the Swedish automaker already offers a wide range of ...

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...

However, hydrogen hasn’t yet caught on as a large-scale solution largely due to funding, even though even the US Department ...

On Thursday, a judge could advance a lawsuit against Toyota filed by owners of the company’s hydrogen-powered Mirai, a ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a ...

A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...